Kalaris Therapeutics, Inc. Common Stock (KLRS)

• Market cap: $131M
• 1 day: -9.13%
• 5 days: -10.68%
• 1 month: -21.92%
• 3 months: -33.37%
• 6 months: -69.23%
• Year to date: -39.42%
• 1 year: -65.68%
• 5 years: -98.93%
• 10 years: -98.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

12% less funds holding

Funds holding: 60 [Q3] → 53 (-7) [Q4]

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

32% less capital invested

Capital invested by funds: $36.3M [Q3] → $24.6M (-$11.7M) [Q4]

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17